Shanghai ZJ Bio-Tech Co (SHSE:688317) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai ZJ Bio-Tech Co EBITDA Margin % Related Terms
Shanghai ZJ Bio-Tech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688317 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a EBITDA Margin % of -88.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #624 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is Shanghai ZJ Bio-Tech Co's EBITDA Margin % too high?
Shanghai ZJ Bio-Tech Co's current EBITDA Margin % is -88.43%. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #624 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #624 out of 816 companies for EBITDA Margin %. This places Shanghai ZJ Bio-Tech Co in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current EBITDA Margin % is -88.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.94, compared to a current price of ¥15.68 — trading 57.7% above its estimated fair value. The current EBITDA Margin % is -88.43%. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current EBITDA Margin % is -88.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.68 is trading 57.7% above its estimated GF Value™ of ¥9.94.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
EBITDA Margin %: -88.43%
GF Value™: ¥9.94 vs. price of ¥15.68 (57.7% above fair value)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
68GF Score
Get the complete analysis for SHSE:688317
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
